| Experts' agency problems: evidence from the prescription drug market in Japan T Iizuka The RAND Journal of Economics 38 (3), 844-862, 2007 | 259 | 2007 |
| The effect of prescription drug advertising on doctor visits T Iizuka, GZ Jin Journal of Economics & Management Strategy 14 (3), 701-727, 2005 | 217 | 2005 |
| Physician agency and adoption of generic pharmaceuticals T Iizuka American Economic Review 102 (6), 2826-58, 2012 | 184 | 2012 |
| An empirical analysis of planned obsolescence T Iizuka Journal of Economics & Management Strategy 16 (1), 191-226, 2007 | 126 | 2007 |
| What explains the use of direct‐to‐consumer advertising of prescription drugs? T Iizuka The Journal of Industrial Economics 52 (3), 349-379, 2004 | 107 | 2004 |
| Direct to consumer advertising and prescription choice T Iizuka, GZ Jin Journal of Industrial Economics 55 (4), 771-771, 2007 | 89 | 2007 |
| Patient cost sharing and medical expenditures for the elderly K Fukushima, S Mizuoka, S Yamamoto, T Iizuka Journal of Health Economics 45, 115-130, 2016 | 86 | 2016 |
| Association of the national health guidance intervention for obesity and cardiovascular risks with health outcomes among Japanese men S Fukuma, T Iizuka, T Ikenoue, Y Tsugawa JAMA Internal Medicine 180 (12), 1630-1637, 2020 | 72 | 2020 |
| Does higher malpractice pressure deter medical errors? T Iizuka The Journal of Law and Economics 56 (1), 161-188, 2013 | 57 | 2013 |
| Robots and labor in the service sector: Evidence from nursing homes K Eggleston, YS Lee, T Iizuka National Bureau of Economic Research, 2021 | 42 | 2021 |
| The effects of direct-to-consumer advertising in the prescription drug markets T Iizuka, GZ Jin SSRN, 2020 | 41 | 2020 |
| Generic entry in a regulated pharmaceutical market T Iizuka The Japanese Economic Review 60 (1), 63-81, 2009 | 41 | 2009 |
| False alarm? Estimating the marginal value of health signals T Iizuka, K Nishiyama, B Chen, K Eggleston Journal of public economics 195, 104368, 2021 | 34 | 2021 |
| Drug Advertising and Health Habit T Iizuka, GZ Jin National Bureau of Economic Research, 2005 | 28 | 2005 |
| The generic drug market in Japan: will it finally take off? T Iizuka, K Kubo Health Economics, Policy and Law 6 (03), 369-389, 2011 | 26 | 2011 |
| Is zero a special price? Evidence from child health care T Iizuka, H Shigeoka American Economic Journal: Applied Economics 14 (4), 381-410, 2022 | 22 | 2022 |
| Promoting innovation in small markets: Evidence from the market for rare and intractable diseases T Iizuka, G Uchida Journal of Health Economics 54, 56-65, 2017 | 22 | 2017 |
| Avoidable hospital admissions from diabetes complications in Japan, Singapore, Hong Kong, and communities outside Beijing J Quan, H Zhang, D Pang, BK Chen, JM Johnston, W Jian, ZY Lau, ... Health Affairs 36 (11), 1896-1903, 2017 | 20 | 2017 |
| The impact of physician supply on the healthcare system: evidence from Japan's new residency program T Iizuka, Y Watanabe Health economics 25 (11), 1433-1447, 2016 | 20 | 2016 |
| Free for children? Patient cost-sharing and healthcare utilization T Iizuka, H Shigeoka National Bureau of Economic Research, 2018 | 17 | 2018 |
Karen EgglestonStanford University在 stanford.edu 的电子邮件经过验证
